PHOENIX, Ariz. -- April 8, 2014 -- The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) awarded a $200,000 grant today to Dr. Michael Barrett of the Translational Genomics Research Institute (TGen).
Dr. Barrett, an Associate Professor in TGen's Clinical Translational Research Division, was one of 14 "outstanding scientists" across the nation named to receive a total of $5 million in grants for pancreatic cancer research.
The grants were announced during the AACR Annual Meeting 2014 in San Diego, April 5-9. With more than 34,000 members, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research.
Specifically, Dr. Barrett was one of five scientists to receive a 2014 Pancreatic Cancer Action Network-AACR Innovative Grant, "intended to promote the development and study of novel ideas and approaches in basic, translational, clinical, or epidemiological research that have direct application and relevance to pancreatic cancer."
Dr. Barrett's project, "Genomic drivers of therapeutic responses in metastatic disease," will investigate the molecular underpinnings of how and why pancreatic cancer spreads to other parts of the body.
"The fundamental hypothesis of this application is that distinct clonal tumor populations that arise during the natural history of pancreatic cancer mediate the clinical responses in patients with metastatic pancreatic cancer," Dr. Barrett said.
"The vision of our work is to bring together advanced genome technologies and the clinical resources available through TGen and our various collaborators to make an immediate impact in the lives of patients with pancreatic cancer and other malignancies," said Dr. Barrett, who also is a consultant with the Mayo Clinic Cancer Center-Arizona.
The grants support research into high-priority areas in an effort to reach the Pancreatic Cancer Action Network's goal to double pancreatic cancer survival by 2020.
"The most promising science has been selected for funding through a rigorous peer-review process. This year's grant recipients hail from leading institutions throughout the country and range from early career investigators continuing to build the field of pancreatic cancer leaders to more senior scientists," said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "Their collective efforts have the potential to answer important questions that could lead to significant scientific advances for pancreatic cancer, and ultimately improve patient outcomes. We look forward to working with our new grantees and welcoming them to our team."
Pancreatic cancer annually takes the lives of more than 38,000 Americans, making it the fourth leading cause of cancer death in the U.S. A staggering 75 percent of those diagnosed die within the first year, and only 6 percent survive more than five years.
"Pancreatic cancer is among the most deadly of cancers," said Margaret Foti, Ph.D., M.D. (h.c.), and Chief Executive Officer of AACR. "With death rates steadily climbing over the past decade, more research into pancreatic cancer is urgently needed. The AACR is, therefore, proud to be partnering with the Pancreatic Cancer Action Network to support cutting-edge scientific research projects that have the potential to lead to major breakthroughs in the prevention, detection, and treatment of this devastating disease."
The Pancreatic Cancer Action Network, in collaboration with the AACR, introduced the grants program in 2003, and has since awarded 108 research grants totaling more than $22 million to bright and motivated scientists across the country with the goals of developing a pipeline of researchers dedicated to studying the disease, supporting innovative ideas and approaches, and enabling the organization to reach its 2020 goal.
About the American Association for Cancer Research Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.
American Association for Cancer Research
In San Diego,April 5-9:412-559-5553
About the Pancreatic Cancer Action Network The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative--The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival. For more information, go to http://www.
Pancreatic Cancer Action Network
In San Diego,April 6-8:562-810-3016
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: http://www.
TGen Senior Science Writer